These findings suggest that targeting specific FGFs (eg, FGF1, FGF5, FGF7, FGF10, FGF16, FGF18, and FGF21) or their receptors (FGFR1c and FGFR3c) may provide novel therapeutic strategies to combat obesity- and aging-related cardiac dysfunction. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.